FMBA plans to test the Convasel vaccine on the elderly in 2022

The Federal Biomedical Agency (FMBA) may conduct a clinical trial of the Convasel coronavirus vaccine in people over 60 this year. This was announced by the head of the agency Veronika Skvortsova, reports TASS.

“Given the experience of conducting such studies, the successful results of preclinical and clinical studies, the FMBA of Russia is considering the possibility of a clinical trial of the Convasel vaccine in people over 60 years of age in 2022,” she said.

FMBA announced the timing of post-registration studies of the vaccine "Konvasel" Society

"Konvasel" is a vaccine against COVID-19 , which was developed by the St. Petersburg Research Institute of Vaccines and Serums of the FMBA of Russia. It is a subunit recombinant drug. It uses parts (subunits) of the virus that the immune system needs to recognize.

The Ministry of Health registered the vaccine in mid-March. On April 5, FMBA announced the launch of the production of the drug. The capacity will allow producing up to 2 million doses of vaccine per month.

Skvortsova announced the possibility of using Konvasel for revaccination Society

According to Skvortsova, specialists conducted a clinical study on revaccination with Konvasel after vaccination with Sputnik V, EpiVacCorona and KoviVac. The trial involved 155 people, it showed that a person can be revaccinated with the drug no earlier than 30 days after the first vaccination.

Read on RBC Pro Pro Amazon: crazy ideas that paid off.Investor's Digestwhich managers will survive in the next two years Articles Pro How the relevance of digital assets and currencies is changing ArticlesPro Put up a golden shield: why e-mail newsletters do not work in China Pro instructions There is no way out:How to Legally Conduct a Reduction Instructions Pro Strength Test:How to Legally Deny a Job Candidate How To How an Accountant Created India's Largest $6 Billion Bank for the Poor Articles ProHow non-residents can be issued from Russian shares and what will happen to the market Articles

In May, the results of a study on the duration of immunity in those vaccinated with Convasel should appear. At the end of summer, FMBA will begin a third phase of clinical trials to evaluate safety, immunogenicity, and preventive efficacy. Tests should last at least six months.